These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 18941113)

  • 21. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
    Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
    Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aged mice develop protective antitumor immune responses with appropriate costimulation.
    Lustgarten J; Dominguez AL; Thoman M
    J Immunol; 2004 Oct; 173(7):4510-5. PubMed ID: 15383582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
    Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM
    J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TLR ligands in the local treatment of established intracerebral murine gliomas.
    Grauer OM; Molling JW; Bennink E; Toonen LW; Sutmuller RP; Nierkens S; Adema GJ
    J Immunol; 2008 Nov; 181(10):6720-9. PubMed ID: 18981089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment.
    Song L; Yang MC; Knoff J; Wu TC; Hung CF
    PLoS One; 2014; 9(12):e115711. PubMed ID: 25531529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy.
    Ding ZC; Huang L; Blazar BR; Yagita H; Mellor AL; Munn DH; Zhou G
    Blood; 2012 Sep; 120(11):2229-39. PubMed ID: 22859605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
    Heckelsmiller K; Beck S; Rall K; Sipos B; Schlamp A; Tuma E; Rothenfusser S; Endres S; Hartmann G
    Eur J Immunol; 2002 Nov; 32(11):3235-45. PubMed ID: 12555669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glatiramer Acetate Complexed with CpG as Intratumoral Immunotherapy in Combination with Anti-PD-1.
    Huang A; Groer C; Lu R; Forrest ML; Griffin JD; Berkland CJ
    Mol Pharm; 2022 Nov; 19(11):4357-4369. PubMed ID: 36282296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
    Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
    PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.
    Chung Y; Qin H; Kang CY; Kim S; Kwak LW; Dong C
    Blood; 2007 Sep; 110(6):2013-9. PubMed ID: 17581919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic administration of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines.
    Šmahel M; Poláková I; Sobotková E; Vajdová E
    Clin Dev Immunol; 2011; 2011():176759. PubMed ID: 22028727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.
    Sagiv-Barfi I; Kohrt HE; Burckhardt L; Czerwinski DK; Levy R
    Blood; 2015 Mar; 125(13):2079-86. PubMed ID: 25662332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
    Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
    Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA.
    Stone GW; Barzee S; Snarsky V; Santucci C; Tran B; Kornbluth RS
    J Thorac Oncol; 2009 Jul; 4(7):802-8. PubMed ID: 19550243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y; Che Y; Zhao Y; Wang X
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.